Free Daily Podcast Summary
The Bio Report: Daily Summaries Delivered
by Levine Media Group
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 3 days ago38 min
Turning the Thymus into an Engine of Immune Tolerance in T1D and Beyond
Type 1 diabetes is still a disease we manage day‑to‑day rather than prevent, and today’s approaches do little to stop the immune system from attacking beta cells in the first place. Zag Bio is trying to change that by turning the thymus, the body’s training ground for T cells, into a therapeutic engine for immune tolerance, using thymus‑homing antibodies to program long‑lived, antigen‑specific Tregs against type 1 diabetes and other autoimmune diseases. Zag Bio CEO Jason Cole discusses type 1 diabetes, how the company’s thymic training platform fits into the emerging tolerance landscape alongside cell therapies and nanoparticle approaches, and the potential to extend this strategy to a broader set of autoimmune diseases.
- 1 weeks ago25 min
Unlocking Major Targets with Mini Proteins
Most small molecule drugs and biologics miss a large group of important receptors in the body. These receptors, known as GPCRs, play big roles in major diseases, but they are unusually hard to target in a precise and safe way. Skape Bio is trying to change that by using artificial intelligence to design an emerging class of therapies known as mini proteins that can fit these receptors snugly and control them in ways traditional drugs often can’t. Christoffer Norn, co‑founder and CEO of Skape Bio, discusses how mini proteins share strengths of both small molecules and biologics while avoiding some of their weaknesses, why the company’s approach could open up new therapeutic opportunities, and how Skape Bio is building a broad pipeline of differentiated GPCR‑targeting therapies.
- 2 weeks ago41 min
Addressing a Data Problem to Enable AI-Drug Discovery
AI’s promise in drug discovery is being held back by a simple but stubborn problem: the field doesn’t have enough of the right kind of lab-generated data to train good models. Public databases and scattered studies give a patchy view of how proteins interact, mostly showing successful interactions and using different methods and conditions, which makes it hard for AI systems to learn broad rules or understand what doesn’t work. A-Alpha Bio tackles this data gap with AlphaSeq, a lab platform that can test around a million protein pairs in one experiment under the same conditions, producing rich, consistent information on both hits and misses that’s well suited for AI. David Younger, co-founder and CEO of A-Alpha Bio, talks about why far more lab data and infrastructure will be needed than most people expect, why current public datasets fall short, and why the company’s business model is built around providing data and services rather than developing its own drugs.
- 3 weeks ago29 min
Turning Multi Specific Antibody Design into an Engineering Discipline with AI
Multi-specific antibodies promise to unlock complex biology that conventional monoclonals can’t touch, but their added mechanisms of action also introduce safety and developability risks. These antibodies—especially T‑cell engagers—behave differently from traditional monospecific antibodies, and seemingly minor architectural tweaks can cause disproportionate shifts in potency, selectivity, and cytokine release. LabGenius is trying to turn multi-specific design from an intuition-driven art into a genuine engineering discipline by generating proprietary data at scale and feeding them back into machine learning models. Angus Sinclair, chief scientific officer of LabGenius, discusses why many safety failures in early solid-tumor T‑cell engagers were effectively locked in at design, how the company’s AI platform engineers multi-specific T‑cell engagers that are both potent and selective in solid tumors, and where AI is actually adding value in multi-specific design today.
- Jul 1, 202630 min
Addressing the Treatment Gap in Ischemic Stroke
Acute ischemic stroke is both ubiquitous and undertreated. Only a small fraction of patients currently receive clot-busting drugs or mechanical thrombectomy because of the small treatment window. That’s because existing therapies require rapid presentation to specialized centers and carry nonreversible bleeding risks that make clinicians hesitant to use them. Basking Biosciences is developing a first-in-class, reversible thrombolytic that targets von Willebrand factor to expand access to safe, effective treatment. Basking Biosciences CEO Julia Owens and co-founder and chief scientific officer Shahid Nimjee discuss the tension between restoring blood flow and causing irreversible intracranial hemorrhage that clinicians face in treating ischemic stroke, the narrow treatment window for existing therapies, and how modulating von Willebrand factor may open a much larger treatment window across a broader range of care settings.
- Jun 24, 202624 min
A Pipeline in a Product that Reimagines Control of Inflammation
Plasma gelsolin is an abundant, endogenous regulator of inflammation that is consumed during severe inflammatory insults. When levels fall too low, patients are at higher risk of organ damage and death, particularly in settings like acute respiratory distress syndrome where a dysregulated inflammatory response floods the lungs with fluid and leaves patients dependent on ventilatory support with no approved therapies today. BioAegis Therapeutics is working to turn recombinant human plasma gelsolin into a pipeline-in-a-product. Susan Levinson, CEO of BioAegis, discusses recombinant human plasma gelsolin as a potential first-in-class treatment for ARDS and other inflammasome-driven conditions, how it modulates cytokine storms without suppressing the immune system, and its potential in other conditions including neurodegenerative diseases.
- Jun 17, 202652 min
Building a Genetics Engine to Crack the Target Bottleneck
A chronic shortage of high‑quality targets remains one of the biggest constraints in drug discovery, even as therapeutic tools become more powerful and diverse. Regeneron is tackling that problem with its Regeneron Genetics Center, which has built a genetics‑driven discovery engine that integrates human genetics with rich clinical data, large‑scale proteomics, and AI‑driven analytics. Aris Baras, head of the Regeneron Genetics Center, discusses how proteomics is reshaping RGC’s view of risk prediction, how AI helps his team sift through hundreds of millions of variants, and what it really takes to scale this kind of effort and translate it into more successful, transformative therapies for patients.
- Jun 10, 202628 min
Stopping Shape-Shifting Tumors with a First-in-Class Epigenetic Drug
Epigenetics, the layer of chemical switches that controls how genes are turned on and off, can act like cancer’s operating system when a single epigenetic enzyme becomes essential for a tumor to survive. K36 Therapeutics is developing first‑in‑class medicines that block an epigenetic enzyme that helps certain multiple myeloma cells grow, change identity to escape treatment, and become resistant to today’s drugs. Terry Connolly, CEO of K36, discusses a new way to fight cancer by changing how cancer cells read their DNA instead of chasing one mutation at a time, how K36’s experimental therapies aim to re‑sensitize tumors to existing treatments, and the potential to create new options for people whose cancers have stopped responding.
Get The Bio Report summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Biohack-it
A weekly exploration of biohacking, holistic health, and science-driven strategies for optimizing physical and mental well-being.
The Dylan Gemelli Podcast
Discussions with health and wellness experts on fitness, biohacking, and performance enhancement to improve quality of life.
The Dr. Hyman Show
Explores root causes of chronic disease and promotes functional medicine, nutrition, and preventive health through expert discussions.
The Dr. Gabrielle Lyon Show
Discusses health, longevity, and mental resilience through science-based conversations with medical and wellness experts.
Unbiased Science
Two scientists analyze health topics using objective, evidence-based approaches to inform everyday decisions.
Inquiring Minds
Explores the intersection of science and society through critical thinking and in-depth analysis.
LONGEVITY with Nathalie Niddam
Explores science-backed strategies for extending healthspan through nutrition, biohacking, peptides, and emerging longevity research.
Science Magazine Podcast
Weekly episodes covering original scientific research, global science news, and expert commentary.
Treated with Dr. Sara Szal
Dr. Sara Szal explores holistic health solutions through conversations with experts and patients seeking mind, body, and soul healing.
The Biology of Trauma With Dr. Aimie
Explores how trauma affects the body on a cellular level and offers a new model for healing in the modern world.
Huberman Lab
Explores neuroscience and science-based tools for understanding and improving brain function, behavior, and health.
Solutions with Henry Blodget
Henry Blodget interviews experts in business, tech, and politics about practical solutions for building a better future.
About The Bio Report
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The Bio Report in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The Bio Report daily summary?
It's a free AI-powered email that summarizes new episodes of The Bio Report as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The Bio Report podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The Bio Report product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Levine Media Group.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does The Bio Report release new episodes?
The Bio Report publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does The Bio Report cover?
The Bio Report covers topics including Science, Business, Medicine, Fitness, Health & Fitness, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The Bio Report summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.